Rep. Josh Gottheimer Sells Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM). In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Tandem Diabetes Care stock on March 19th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 3/24/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 3/24/2025.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Pacific Premier Bancorp (NASDAQ:PPBI) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Azenta (NASDAQ:AZTA) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Chord Energy (NASDAQ:CHRD) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Endava (NYSE:DAVA) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/19/2025.

Tandem Diabetes Care Stock Performance

TNDM stock traded up $0.02 during trading hours on Friday, hitting $17.06. 1,227,088 shares of the stock were exchanged, compared to its average volume of 1,500,334. Tandem Diabetes Care, Inc. has a 12 month low of $15.75 and a 12 month high of $53.69. The firm has a market capitalization of $1.13 billion, a P/E ratio of -8.84 and a beta of 1.52. The company has a 50-day simple moving average of $23.62 and a two-hundred day simple moving average of $30.82. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.

Wall Street Analysts Forecast Growth

TNDM has been the topic of several recent research reports. Citigroup cut shares of Tandem Diabetes Care from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $35.00 to $24.00 in a report on Tuesday, March 4th. Sanford C. Bernstein lowered Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $35.00 to $25.00 in a research note on Friday, February 28th. Canaccord Genuity Group reiterated a “buy” rating and set a $63.00 target price on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Mizuho initiated coverage on Tandem Diabetes Care in a report on Thursday. They set a “neutral” rating and a $20.00 target price on the stock. Finally, The Goldman Sachs Group dropped their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Nine equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.88.

Insiders Place Their Bets

In other news, COO Jean-Claude Kyrillos acquired 10,538 shares of Tandem Diabetes Care stock in a transaction dated Friday, March 7th. The shares were bought at an average cost of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 2.20% of the company’s stock.

Institutional Trading of Tandem Diabetes Care

Hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its holdings in Tandem Diabetes Care by 134.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company’s stock worth $8,379,000 after acquiring an additional 113,355 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Tandem Diabetes Care by 163.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock worth $65,000 after purchasing an additional 1,101 shares during the period. US Bancorp DE grew its stake in shares of Tandem Diabetes Care by 15.2% in the fourth quarter. US Bancorp DE now owns 38,708 shares of the medical device company’s stock worth $1,394,000 after purchasing an additional 5,108 shares during the last quarter. KBC Group NV increased its holdings in Tandem Diabetes Care by 41.5% in the fourth quarter. KBC Group NV now owns 192,479 shares of the medical device company’s stock valued at $6,933,000 after purchasing an additional 56,461 shares during the period. Finally, Envestnet Portfolio Solutions Inc. raised its position in Tandem Diabetes Care by 22.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company’s stock worth $236,000 after purchasing an additional 1,184 shares during the last quarter.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.